{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T07:08:26Z","timestamp":1747379306869},"reference-count":0,"publisher":"Danish Medical Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>INTRODUCTION. Pharmacokinetic drug-drug interactions (DDIs) are challenging aspects of direct oral anticoagulant (DOAC) therapy in patients with cancer. We evaluated the prevalence of potential DOAC\/antineoplastic agent DDIs and the one-year cumulative incidence of switching from low-molecular-weight heparin (LMWH) to a DOAC in patients with cancer.  METHODS. Patients with cancer and an indication of LMWH were included from Herlev and Gentofte Hospital, Denmark, in the 2014-2019 period. Follow-up was initiated when the first dose of LMWH was dispensed. Data were obtained from electronic medical records. One-year cumulative incidence of switching from LMWH to DOAC was estimated using the Aalen-Johansen estimator. Potential DDIs were evaluated using a report from the European Heart Rhythm Association (EHRA) and a review by Hellfritzsch et al.  RESULTS. A total of 161 patients were included with a median age of 70.8 (interquartile range: 64.2-76.1) years. The one-year cumulative incidence of switching from LMWH to DOAC was 32% (95% confidence intervals: 21-43%) in patients eligible for DOACs. Using the EHRA report, a total of 24% of antineoplastic agents were not identified. This percentage decreased to 8% using data from Hellfritzsch et al.  CONCLUSIONS. In patients with cancer, the one-year cumulative incidence of switching from LMWH to DOAC was &lt; 35% in patients eligible for DOAC, revealing a potential for improved anticoagulant treatment. Furthermore, contemporary data elaborated on potential DDIs between DOACs\/antineoplastic agents.  FUNDING. \u201cHelsefonden\u201d (21-B-0350) and the \u201cKaren Elise Jensens Fonden\u201d (29-4-2021) funded the study.  TRIAL REGISTRATION. Not relevant.<\/jats:p>","DOI":"10.61409\/a05230278","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:40:35Z","timestamp":1706694035000},"page":"1-10","source":"Crossref","is-referenced-by-count":1,"title":["Infrequent transition to direct oral anticoagulants in patients with cancer"],"prefix":"10.61409","volume":"71","author":[{"given":"Nina","family":"Nouhravesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Sindet-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Hellfritzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Akil","family":"Al-Alak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"K\u00fcmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik L.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,1,25]]},"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:40:37Z","timestamp":1706694037000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A05230278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.61409\/a05230278","relation":{},"ISSN":["2245-1919"],"issn-type":[{"value":"2245-1919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}